Publicacions en què col·labora amb María Jesús Monte Río (105)

2024

  1. Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition

    Biochemical Pharmacology

  2. Relationship between cholestasis and altered progesterone metabolism in the placenta-maternal liver tandem

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 2

2022

  1. Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia

    Hepatology, Vol. 76, Núm. 5, pp. 1259-1274

  2. Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers

    Cancers, Vol. 14, Núm. 14

  3. Impact of Liver Inflammation on Bile Acid Side Chain Shortening and Amidation

    Cells, Vol. 11, Núm. 24

  4. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation

    Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004

2021

  1. Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis

    Molecular Therapy - Methods and Clinical Development, Vol. 22, pp. 210-221

  2. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics

    Aging, Vol. 13, Núm. 19, pp. 23416-23434

  3. Novel pharmacological options in the treatment of cholangiocarcinoma: Mechanisms of resistance

    Cancers, Vol. 13, Núm. 10

  4. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway

    Journal of Hepatology, Vol. 74, Núm. 6, pp. 1429-1441

2020

  1. Cellular mechanisms accounting for the refractoriness of colorectal carcinoma to pharmacological treatment

    Cancers, Vol. 12, Núm. 9, pp. 1-34

  2. Clinical relevance of the relationship between changes in gut microbiota and bile acid metabolism in patients with intrahepatic cholangiocarcinoma

    HEPATOBILIARY SURGERY AND NUTRITION

  3. JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 28, pp. 16492-16499

  4. Molecular bases of drug resistance in hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 6, pp. 1-26

  5. Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: A machine-learning approach

    Cancers, Vol. 12, Núm. 6, pp. 1-30

  6. Role of genetic variations in the hepatic handling of drugs

    International Journal of Molecular Sciences, Vol. 21, Núm. 8

2019

  1. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy

    Hepatology, Vol. 70, Núm. 4, pp. 1246-1261

  2. Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps

    Archives of Toxicology, Vol. 93, Núm. 3, pp. 623-634

  3. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

  4. The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis

    Hepatology, Vol. 69, Núm. 4, pp. 1632-1647